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Medication assisted treatment with 
buprenorphine/naloxone or methadone: 
Comparitive outcomes in patients with an 
opioid addiction 
DEEPTI SHANBHAG, Wayne State University School of Medicine, gf8278@wayne.edu 
 
ABSTRACT A clinical decision report appraising Hser YI, Evans E, Huang D, et al. Long‐term outcomes after randomization to 
buprenorphine/naloxone versus methadone in a multi‐site trial. Addiction. 2016;111(4):695-705. https://doi.org/10.1111/add.13238 
for a patient with addiction to prescription opioids. 
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Clinical Context 
David Green (pseudonym) is a 54 y.o. male with an opioid use disorder, and a history of an alcohol use disorder 
with 1 year of sobriety. Mr. Green was first prescribed oxycodone for injuries from a car accident in his early 30s. 
Ever since his musculoskeletal injuries healed, he has struggled with an addiction to opioid analgesics. In order to 
sustain his addiction, over the years, Mr. Green has repeatedly engaged in self-harm in order to obtain new 
prescriptions. His addiction has strained his relationship with his wife and 2 teenage children, and diminished his 
productivity as a contractor. Desperate to mend his relationship with his family, and regain financial stability, Mr. 
Green wants to know about his options when considering medication assisted treatment for opioid addiction, 
namely whether buprenorphine/naloxone treatment offered at the clinic is as effective as methadone treatment. 
Clinical Question 
Is buprenorphine/naloxone as effective as methadone in medication assisted treatment for prescription opioid use disorder?  
Research Article 
Hser YI, Evans E, Huang D, et al. Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐
site trial. Addiction. 2016;111(4):695-705. https://doi.org/10.1111/add.13238.  
Related Literature 
A search of PubMed was done using the following fields: methadone AND opioid AND (buprenorphine/naloxone OR buprenorphine-
naloxone) AND (prescription OR oral OR analgesic OR analgesia) NOT (pregnant OR pregnancy) 
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This search resulted in 210 articles. Filtering for clinical trials and full-text articles narrowed the results to 43 articles. Upon review of 
titles and abstracts, 5 articles directly compared the effectiveness of buprenorphine/naloxone and methadone in patients with an 
opioid use disorder.  
Law et al. conducted a double-blind randomized controlled trial (RCT) from 1998-2000 at an outpatient specialist drug clinic in the 
UK, of 80 individuals with ⩽ 3 years of opioid dependency, as defined by DSM-IV. Patients underwent a short-term treatment 
program involving induction/stabilization on methadone or buprenorphine/naloxone, followed by detoxification. The main outcome 
measures were urine drug screens for opiates, and withdrawal and craving questionnaires. There were no overall differences in 
positive urine drug screens and drop-outs during any phase of the study. While this was a well-designed study, it was excluded 
because the induction/stabilization phase only lasted a brief period of 2-6 weeks, followed by a detoxification phase of 2.5 weeks, 
during which medication assistance, either with buprenorphine/naloxone or methadone was gradually withdrawn.1  
Potter et al. conducted a randomized open-label study from 2006 to 2009 of 1269 patients randomized to receive either methadone 
or buprenorphine/naloxone. Participants completed a 24-week active medication phase, and treatment outcomes were opioid use 
during the final 30 days of treatment. This study was unique in that it’s primary objective was to explore differences in opioid 
replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (injector 
or non-injector) of opioid use. The study concluded that there is no evidence of superiority of buprenorphine/naloxone over 
methadone for opioid analgesic users. However, this study was excluded due to a lack of reported statistics to support the 
conclusions.2 
Neumann et al. conducted an RCT in which 54 patients with chronic pain and opioid addiction were randomized to receive either 
buprenorphine/naloxone or methadone. At 6-month follow-up, both groups reported reduction in pain relative to baseline, but 
compared to 5 in the buprenorphine group, none in the methadone group reported illicit opioid use. While this was a well-designed 
study, it was excluded due to the small sample size. Additionally, the study focused exclusively on patients with existing chronic pain, 
which is not applicable to this clinical context.3 
McKeganey et al. conducted a prospective cohort study comparing 71 individuals who were either on methadone or 
buprenorphine/naloxone. Results showed that when controlling for a number of patient-level covariates, both methadone and 
Buprenorphine/naloxone significantly reduced current users' days of heroin use between the 90 days prior to intake and at the 8-
month follow-up, with buprenorphine/naloxone yielding a significantly larger magnitude reduction in heroin use days than 
methadone. This study was excluded because it used an observational rather than controlled study design, used a small sample size, 
and only included heroin users rather than patients dependent on opioid analgesics.4 
Hser et al. conducted a follow-up from 2011–2014 of 1,080 opioid-dependent participants enrolled in opioid treatment programs in 
the USA between 2006 and 2009, randomized to receive open-label buprenorphine/naloxone or methadone for up to 24 weeks. 
Outcomes were mortality and opioid use. While mortality rates did not differ significantly between the two groups, opioid use at 
follow-up was higher among participants randomized to buprenorphine/naloxone relative to methadone. This study was ultimately 
selected because it was a rigorous RCT with a large sample size. Additionally, the sample group included patients using opioid 
analgesics and reported outcomes relevant to the patient context.5 This article had the highest internal and external validity.  
Using the SORT criteria, the Grade of Recommendation is B, based on consistent studies of mixed methodologies of fair 
methodological quality.6 
Critical Appraisal 
Hser et al. performed a follow-up in 2011–2014 of 1,080 opioid-dependent participants entering 7 opioid treatment programs in the 
USA between 2006 and 2009 and randomized to receive open-label buprenorphine/naloxone or methadone for up to 24 weeks; 795 
participants completed in-person interviews (~74% follow-up interview rate). Outcomes included mortality and continued opioid 
use.5 Based on the Strength of Recommendations Taxonomy (SORT) criteria, this study would be classified as Level 2.6 
The study authors carefully document demographic details for the 795 patients as follows: mean age at baseline was 37.4, 34.1% 
were female, 72.6% white, 11.2% Hispanic, 9.2% African American, and 7.0% other race/ethnicity. The two medication groups were 
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all similar in baseline measures except that more participants in the methadone group reported cocaine use (37.2%) than in the 
buprenorphine/naloxone group (30.2%). While the demographic similarities between the groups suggests that randomization was 
successful and minimized selection bias, the tools and exact methods of randomization were not detailed in the paper. Because of 
higher dropout rate in the BUP group, the randomization protocol was changed from 1:1 to 2:1, favoring buprenorphine midway 
through the study. The study performed a sensitivity analysis to ensure that there were no differences in the demographic 
characteristics of participants included (n=795) and omitted (n=285) from analysis, to assess participation bias.5 Yet, this is a 
significant loss of follow up precluding an intention to treat analysis, which was not attempted.  
While the study was not blinded, outside of the treatment, both groups of patients were treated equally. Enrollment occurred 
during 2006-2009 and assessment occurred during 2011-2014 Using timeline follow back (TLFB). This was poorly described, leaving 
the reader with the impression that a single follow up interview was used to impute monthly rates over a five-year time interval, 
exposing the data to significant recall bias. Also not described is the fact that methadone requires daily supervised treatment, but 
the protocol for BUP was not described, leading the reader to wonder if the two groups were treated similarly or not. This 
introducing a large bias if the two groups were not treated similarly, particularly as this was an open label trial. 
The study considered clinically relevant outcomes in patients being treated for opioid dependence disorders, namely mortality rates 
and continued opioid use.5 However, the study may have been enhanced by consideration of patient-centered quality of life 
measures. While the average age of the patients in the study was slightly younger than that of our patient, the ethnic composition of 
the study subjects matches our patient.  
There were 23 deaths in the buprenorphine/naloxone group (n=630, or 3.6%) and 26 deaths in the methadone group (n=450, or 
5.8%); the difference was not statistically different (X2(1)=2.74; p=.10). The hazard ratio in the Cox regression that included 
covariates (age, gender, race/ethnicity, cocaine use at the baseline) showed no difference in time to death between the two 
randomized conditions (X2(1)=2.71; p=.10). Opioid use was higher among participants randomized to buprenorphine/naloxone 
relative to methadone at the follow-up interview. Opioid use was assessed by a positive urine test or self-reported past-30-day 
opioid use with significantly more opioid use among buprenorphine/naloxone than methadone participants (50.9% vs. 41.1%, effect 
size (h)=0.20 [0.06, 0.34]. While the difference in the percent of patients using opioids at the time of follow up was found to be 
statistically significant, it is not clear whether this result is clinically meaningful, when considering other factors such as cost and 
accessibility of each treatment. 
Clinical Application 
Mr. Green is a middle-aged man who works as a contractor and has a young family with whom he would like to 
reconcile and maintain a healthy relationship. He primarily struggles with dependence on opioid analgesics, and 
has never used heroin or injection drugs. He also has no other comorbidities. While the study conducted by Hser et 
al. considered a sample population that included patients with dependence on opioid analgesics, they also 
considered individuals using heroin or a combination of the two, and the reported results were not stratified by 
patient type. Hser et al. found a statistically significant difference between buprenorphine/naloxone and 
methadone with more patients continuing to use opioids in the buprenorphine/naloxone group compared to 
methadone. However, the clinical significance of these result is less clear.  
A recent systematic review by Srivastava et al. comparing research on methadone and buprenorphine/naloxone 
concluded that while methadone has higher treatment retention rates, buprenorphine/naloxone has a lower risk 
of overdose.7 They conclude that ultimately, medication assisted treatment is superior to abstinence-based 
treatment and that patient characteristics should drive the decision between methadone and 
buprenorphine/naloxone. Srivastava et al. suggest that for patients at high risk of dropout (such as adolescents 
and socially unstable patients), treatment retention should take precedence over other clinical considerations. For 
patients with high risk of toxicity (such as patients with heavy alcohol or benzodiazepine use), safety would likely 
be the first consideration. Given that Mr. Green is relatively socially stable, and has a history of alcohol abuse, 
buprenorphine/naloxone would be favored over methadone. Furthermore, buprenorphine/naloxone is preferred 
over methadone in patients whose work or family responsibilities make it difficult to attend the pharmacy daily. 
Methadone programs dispense methadone, with its high risk of overdose, under daily supervision during the first 
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few months of treatment. Alternatively, buprenorphine/naloxone can safely be dispensed as take-home doses 
earlier on in treatment if the patient is at low risk of diversion. Given the clinical context of our patient, 
buprenorphine/naloxone therapy seemed to be the more reasonable option. Mr. Green also particularly 
appreciated that he could receive buprenorphine/naloxone therapy from his primary care physician with whom he 
already has an established relationship. 
New Knowledge Related to Clinical Decision Science 
Mr. Green had the opportunity to discuss his treatment options and access MAT because he happened to have established care with 
a primary care physician who was licensed to prescribe buprenorphine/naloxone. However, many patients face barriers to MAT due 
to few physicians prescribing buprenorphine and insurance prior authorizations that can delay or deny access to therapy.8 In 2000, 
the Drug Addiction Treatment Act (DATA 2000) expanded access to treatment for opioid use disorder by legalizing office-based 
maintenance therapy.9 To obtain a DATA 2000 waiver, physicians must notify the Substance Abuse and Mental Health Services 
Administration of their intent to begin prescribing this treatment, have a state medical license and a Drug Enforcement 
Administration number, and complete eight hours of training. Despite these efforts to make MAT more accessible in the primary 
care setting, physician uptake of buprenorphine has been limited for a number of reasons, including physician concerns about 
diversion, stigma toward substance use disorders, concerns about appropriate reimbursement, and time capacity.10  
In 2016, 1.8 million Americans had a substance use disorder involving prescription pain medications.11 Between 2000 and 2015, over 
500,000 individuals died from opioid overdose, with deaths rising with prescription opioid sales.12 As the largest prescribers of 
opioids, primary care physicians have an important role in reversing these trends.13 In conjunction with continued use of methadone 
clinics, increasing the number of primary care physicians who prescribe buprenorphine is critical to making MAT more accessible for 
patients such as Mr. Green. 
Questions raised using Clinical Decision Science change the type of questions and type of data needed to treat patients with opiate 
use disorder. Instead of focusing on patient level data, we need more physician level data. What are the drivers of uptake for MAT 
among providers? The body-politic has alternately blamed pharmaceutical companies—and physicians for creating an opioid use 
epidemic. What is the role of “courage” to engage patients that have a high-risk disorder? What risks are there to physician 
reputation? What difficulties prevent this treatment from becoming more widely available? This questions often can only be 
answered using social context data and analysis. This story began years ago and is currently evolving. Different clinical research is 
needed to help patients with this dangerous condition. 
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